Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Nvidia Options Price in $280 Billion Earnings Swing 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Tesla Raises Cybertruck Prices by $5,000 in US 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Add as a preferred source on Google
RESEARCH TRIANGLE PARK, N.C., April 26, 2018 -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its first quarter 2018 financial results will be reported on Tuesday, May 8, 2018.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.
Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at https://biocryst.gcs-web.com/events.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule medicines that address both common and rare conditions. BioCryst has several ongoing development programs including BCX7353, an oral treatment for hereditary angioedema, galidesivir, a potential treatment for filoviruses, and a preclinical program to develop oral Alk-2 inhibitors for the treatment of fibrodysplasia ossificans progressive (FOP). RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at https://biocryst.gcs-web.com/financial-information/sec-filings.
BCRXW
CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910
